Acasti Pharma Inc. Logo

Acasti Pharma Inc.

ACST.V

(0.0)
Stock Price

0,58 CAD

-42.12% ROA

-70.24% ROE

-0.68x PER

Market Cap.

18.947.537,98 CAD

0% DER

0% Yield

-336.12% NPM

Acasti Pharma Inc. Stock Analysis

Acasti Pharma Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Acasti Pharma Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Acasti Pharma Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Acasti Pharma Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Acasti Pharma Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Acasti Pharma Inc. Revenue
Year Revenue Growth
2017 0
2018 7.629.000 100%
2019 11.942.000 36.12%
2020 19.584.000 39.02%
2021 18.448.000 -6.16%
2022 14.249.000 -29.47%
2023 27.468.000 48.13%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Acasti Pharma Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2017 9.772.000
2018 21.965.000 55.51%
2019 46.312.000 52.57%
2020 54.787.000 15.47%
2021 82.853.000 33.87%
2022 68.645.000 -20.7%
2023 98.500.000 30.31%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Acasti Pharma Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2017 4.385.000
2018 6.844.000 35.93%
2019 16.715.000 59.05%
2020 17.706.000 5.6%
2021 17.066.000 -3.75%
2022 18.540.000 7.95%
2023 19.648.000 5.64%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Acasti Pharma Inc. EBITDA
Year EBITDA Growth
2017 -13.759.000
2018 -20.540.000 33.01%
2019 -48.018.000 57.22%
2020 -49.135.000 2.27%
2021 -77.034.000 36.22%
2022 -69.553.000 -10.76%
2023 -88.732.000 21.61%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Acasti Pharma Inc. Gross Profit
Year Gross Profit Growth
2017 -9.772.000
2018 -14.336.000 31.84%
2019 -34.370.000 58.29%
2020 -33.549.000 -2.45%
2021 -62.495.000 46.32%
2022 -52.966.000 -17.99%
2023 -71.032.000 25.43%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Acasti Pharma Inc. Net Profit
Year Net Profit Growth
2017 -12.723.000
2018 -16.236.999 21.64%
2019 -43.037.000 62.27%
2020 -44.082.000 2.37%
2021 -75.665.000 41.74%
2022 -64.915.000 -16.56%
2023 -76.264.000 14.88%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Acasti Pharma Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2017 -14
2018 -18 23.53%
2019 -2 -750%
2020 -2 -100%
2021 -2 50%
2022 -1 0%
2023 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Acasti Pharma Inc. Free Cashflow
Year Free Cashflow Growth
2017 -13.210.000
2018 -17.148.000 22.96%
2019 -43.730.000 60.79%
2020 -41.710.000 -4.84%
2021 -78.597.000 46.93%
2022 -25.014.000 -214.21%
2023 -27.137.000 7.82%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Acasti Pharma Inc. Operating Cashflow
Year Operating Cashflow Growth
2017 -11.913.000
2018 -14.998.000 20.57%
2019 -41.731.000 64.06%
2020 -39.339.000 -6.08%
2021 -66.016.000 40.41%
2022 -19.997.000 -230.13%
2023 -24.119.000 17.09%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Acasti Pharma Inc. Capital Expenditure
Year Capital Expenditure Growth
2017 1.297.000
2018 2.150.000 39.67%
2019 1.999.000 -7.55%
2020 2.371.000 15.69%
2021 12.581.000 81.15%
2022 5.017.000 -150.77%
2023 3.018.000 -66.24%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Acasti Pharma Inc. Equity
Year Equity Growth
2017 62.118.000
2018 44.399.000 -39.91%
2019 117.899.000 62.34%
2020 156.123.000 24.48%
2021 89.592.000 -74.26%
2022 102.517.000 12.61%
2023 95.051.000 -7.85%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Acasti Pharma Inc. Assets
Year Assets Growth
2017 73.732.000
2018 68.251.000 -8.03%
2019 143.745.000 52.52%
2020 187.817.000 23.47%
2021 126.045.000 -49.01%
2022 170.454.000 26.05%
2023 164.010.000 -3.93%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Acasti Pharma Inc. Liabilities
Year Liabilities Growth
2017 11.614.000
2018 23.852.000 51.31%
2019 25.846.000 7.71%
2020 31.694.000 18.45%
2021 36.453.000 13.06%
2022 67.937.000 46.34%
2023 68.959.000 1.48%

Acasti Pharma Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.19
Net Income per Share
-0.63
Price to Earning Ratio
-0.68x
Price To Sales Ratio
0.92x
POCF Ratio
-1.41
PFCF Ratio
-0.51
Price to Book Ratio
0.49
EV to Sales
-4.32
EV Over EBITDA
1.15
EV to Operating CashFlow
2.68
EV to FreeCashFlow
2.37
Earnings Yield
-1.47
FreeCashFlow Yield
-1.98
Market Cap
0,02 Bil.
Enterprise Value
-0,09 Bil.
Graham Number
3.48
Graham NetNet
0.36

Income Statement Metrics

Net Income per Share
-0.63
Income Quality
0.48
ROE
-0.7
Return On Assets
-0.42
Return On Capital Employed
-0.65
Net Income per EBT
1.01
EBT Per Ebit
0.85
Ebit per Revenue
-3.91
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0.87
Research & Developement to Revenue
4.03
Stock Based Compensation to Revenue
0.14
Gross Profit Margin
-2.96
Operating Profit Margin
-3.91
Pretax Profit Margin
-3.34
Net Profit Margin
-3.36

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.3
Free CashFlow per Share
-0.34
Capex to Operating CashFlow
0.13
Capex to Revenue
-0.21
Capex to Depreciation
-1.36
Return on Invested Capital
-0.85
Return on Tangible Assets
-0.42
Days Sales Outstanding
11.99
Days Payables Outstanding
40.03
Days of Inventory on Hand
0
Receivables Turnover
30.44
Payables Turnover
9.12
Inventory Turnover
81423999
Capex per Share
-0.04

Balance Sheet

Cash per Share
0,98
Book Value per Share
0,86
Tangible Book Value per Share
0.86
Shareholders Equity per Share
0.86
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
1.39
Current Ratio
3.44
Tangible Asset Value
0,10 Bil.
Net Current Asset Value
0,07 Bil.
Invested Capital
0
Working Capital
0,10 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
0.5
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Acasti Pharma Inc. Dividends
Year Dividends Growth

Acasti Pharma Inc. Profile

About Acasti Pharma Inc.

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

CEO
Ms. Janelle D'Alvise
Employee
0
Address
3009 boulevard de la Concorde East
Laval, H7E 2B5

Acasti Pharma Inc. Executives & BODs

Acasti Pharma Inc. Executives & BODs
# Name Age
1 Mr. Prashant Kohli
Chief Commercial Officer
70
2 Dr. Yves Lachance Ph.D.
Vice President of Quality & Compliance
70
3 Ms. Christine Pelletier
Senior Director of HR
70
4 Mr. Brian D. Ford CPA, CA
Chief Financial Officer
70
5 Ms. Janelle D'Alvise
Pres, Chief Executive Officer, Corporation Sec. & Director
70
6 Dr. Pierre Lemieux M.D., Ph.D.
Co-Founder, Chief Operating Officer & Chief Scientific Officer
70
7 Dr. George Kottayil
Chief Operating Officer of US
70

Acasti Pharma Inc. Competitors